SLX1B-SULT1A4: A Potential Drug Target and Biomarker (G100526831)

Target Name: SLX1B-SULT1A4

NCBI ID: G100526831

SLX1B-SULT1A4

Other Name(s): SLX1B-SULT1A4 readthrough (NMD candidate)

SLX1B-SULT1A4: A Potential Drug Target and Biomarker

SLX1B (Sirtuin-like protein X1B) and SULT1A4 (Sirtuin-like protein 1A4) are highly conserved non-coding RNAs that are expressed in various tissues and organs, including the brain, heart, and kidneys. These non-coding RNAs have been implicated in a wide range of physiological processes, including cellular stress response, DNA damage repair, and metabolism. In recent years, the characterization of SLX1B and SULT1A4 has led to the hypothesis that they may serve as potential drug targets or biomarkers for a variety of diseases.

SLX1B is a 21-kDa protein that is highly conserved in both its amino acid sequence and its gene expression levels. SLX1B is expressed in various tissues, including the brain, heart, and kidneys, and has been shown to play a role in a wide range of physiological processes, including stress response, DNA damage repair, and metabolism. For example, SLX1B has been shown to be involved in the cellular stress response, as it has been shown to interact with various stress-responsive transcription factors, including NF-kappa-B and AP-1. Additionally, SLX1B has been shown to play a role in DNA damage repair, as it has been shown to interact with various DNA damage repair proteins, including DNA repair factors 1 and 5.

SULT1A4 is a 22-kDa protein that is also highly conserved in both its amino acid sequence and its gene expression levels. SULT1A4 is expressed in various tissues, including the brain, heart, and kidneys, and has been shown to play a role in a wide range of physiological processes, including stress response, DNA damage repair, and metabolism. For example, SULT1A4 has been shown to be involved in the cellular stress response, as it has been shown to interact with various stress-responsive transcription factors, including NF-kappa-B and AP-1. Additionally, SULT1A4 has been shown to play a role in DNA damage repair, as it has been shown to interact with various DNA damage repair proteins, including DNA repair factors 1 and 5.

The conservation of SLX1B and SULT1A4 across different species suggests that they may be important targets for drug development, as they are highly conserved and have been implicated in a wide range of physiological processes. Additionally, the involvement of SLX1B and SULT1A4 in the cellular stress response and DNA damage repair processes suggests that they may be useful biomarkers for assessing the severity and effectiveness of certain therapies.

In conclusion, SLX1B and SULT1A4 are potential drug targets and biomarkers that have been shown to play a role in a wide range of physiological processes. Further research is needed to fully understand the potential of SLX1B and SULT1A4 as drug targets and biomarkers, as well as their potential clinical applications.

Protein Name: SLX1B-SULT1A4 Readthrough (NMD Candidate)

The "SLX1B-SULT1A4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLX1B-SULT1A4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets